What is CIDP?

Chronic inflammatory demyelinating polyradiculoneuropathy is an acquired demyelinating peripheral neuropathy that is thought to be an autoimmune disorder. It is considered the chronic variant of Guillain-Barre syndrome.

What do patients take to treat CIDP and its symptoms?

Commonly prescribed and frequently used treatments

Treatment name Efficacy Overall rating of side effects # of Evaluations
Amitriptyline
(Laroxyl, Tryptanol, Tryptizol, Anapsique)
2
Gabapentin
(Gralise, DOM-Gabapentin, PMS-Gabatentin, APO-Gabapentin)
1
Intravenous Immuno Globulin IVIg
(Gammagard, Pentaglobin, Sandoglobuline, Carimune)
1
Prednisone
(Encorton, Deltasone, Pronizon)
1
Methylprednisolone
(Urbason solubile, Methylprednisolon AL, Advantan, Medrol DosePak)
1
Duloxetine
(Yentreve, Cymbalta)
1
Topiramate
(Topamax Sprinkle, Topamax, Topictal, Toprel)
0
Carbamazepine
(Hermolepsin retard, Teril, Carbatrol ER, Epitol)
0
Pregabalin
(Lyrica)
0
Desipramine
(Pertofrane, Norpramin)
0
Venlafaxine
(Odven SBK, Pracet, Zarelis, Venlor XR)
0
Tramadol
(Mabron, Tramium, Zydol SR, Ralivia)
0

These charts show data from CIDP patients' latest treatment evaluations

Who has CIDP at PatientsLikeMe?

<20 20-29 30-39 40-49 50-59 60-69 70+
Current Age
Distribution of females vs. males
Gender
58% Females
42% Males
Age at first symptom
Age at first symptom # of patients Proportion
0-19 yrs 1
20-29 yrs 5
30-39 yrs 3
40-49 yrs 9
50-59 yrs 9
60-69 yrs 5
70+ yrs 1
Diagnosis status
Diagnosis status # of patients Proportion
Diagnosed 38

These charts show data from CIDP patients who have completed their condition history